Skip to content

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05127096
Enrollment
1000
Registered
2021-11-19
Start date
2020-12-15
Completion date
2022-12-30
Last updated
2021-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer Screening

Brief summary

The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.

Interventions

DIAGNOSTIC_TESTFirstSight blood test

FirstSight blood test for colorectal cancer screening

Sponsors

CellMax Life
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

To enroll in Cohort A, a subject must: * Be 45-80 years of age (inclusive) at the time of screening. * Be recently diagnosed with primary colorectal cancer or advanced adenoma with plans to surgically remove the target lesion. To enroll in Cohort B, a subject must: * Be 45-80 years of age (inclusive) at the time of screening. * Be planning to undergo a screening colonoscopy within 30 days after providing signed informed consent.

Exclusion criteria

To enroll in Cohort A, a subject must NOT have: * Inflammatory bowel disease (IBD) * Personal or family history of colorectal cancer syndromes or other hereditary cancer syndromes To enroll in Cohort B, a subject must NOT have: * Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer. * Personal or family history of Familial adenomatous polyposis (FAP). * Personal or family history of Hereditary non-polyposis colorectal cancer syndrome (HNPCC or Lynch Syndrome). * Positive fecal occult blood testing (FOBT) within the previous 6 months. * Positive fecal immunochemical testing (FIT) in the previous 6 months. * Colorectal resection for any reason other than sigmoid diverticular disease. * Overt rectal bleeding within the previous 30 days. * Personal history of any cancer diagnosed \<5 years prior. * Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease. * Colonoscopy within the previous 9 years. * Barium enema, computed tomographic colonography, or sigmoidoscopy within the previous 5 years. * ≥ 2 first-degree relatives who have been diagnosed with colorectal cancer (Note: First degree relatives include parents, siblings and offspring). * 1 first-degree relative with CRC diagnosed before the age of 60. * Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 30 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. * Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.

Design outcomes

Primary

MeasureTime frame
Sensitivity for CRC of the FirstSight test30 days
Specificity of the FirstSight test30 days

Countries

United States

Contacts

Primary ContactBen Hsieh, PhD
ben@cellmaxlife.com650-814-8088
Backup ContactStephen Su, PhD
stephensu@cellmaxlife.com408-887-7640

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026